Oncolytics Biotech is trading at $0.50, up +5.32%, following its announcement of new pelareorep method-of-use patents; coverage has not confirmed the announcement caused the rebound. - Patents were announced in several countries, with a corresponding U.S. patent expected soon. - The strategy could extend protection for certain uses into the late 2040s, subject to issuance and applicable terms. - Shares rebounded after the prior session’s decline while the biotech sector fell 2.01%; sector weakness does not explain the gain.